Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

As one of the hand­ful of drugs-in-de­vel­op­ment for gas­tro­pare­sis, Van­da Phar­ma­ceu­ti­cals’ $VN­DA tradip­i­tant has set it­self apart for the con­di­tion that af­fects about 6 mil­lion in the Unit­ed States and has not seen an ap­proval in near­ly four decades. On Mon­day, the drug­mak­er re­leased mid-stage da­ta that im­pressed, show­ing the drug con­ferred a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in nau­sea symp­toms and nau­sea-free days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.